Pharmaceutical News

RSS

Study examines if antidepressants can benefit patients with osteoarthritis

A clinical trial published in Arthritis & Rheumatology recently examined whether duloxetine, a medication that is prescribed to treat depression and may also reduce chronic pain, can benefit patients with hip or knee osteoarthritis.

6 Jan 2022

New engineered nanomaterials help capture chemotherapy drugs to avoid tissue damage

Standard chemotherapies may efficiently kill cancer cells, but they also pose significant risks to healthy cells, resulting in secondary illness and a diminished quality of life for patients. To prevent the previously unavoidable damage, researchers, led by Penn State, have developed a new class of nanomaterials engineered to capture chemotherapy drugs before they interact with healthy tissue.

6 Jan 2022

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Researchers determine the cross-reactivity of the SARS-CoV-2 spike glycoprotein-induced antibodies before and after a third SARS-CoV-2 vaccine dose.

5 Jan 2022

Monoclonal antibody treatment of COVID-19 reduces viral shedding

Researchers aim to understand the potential benefits of mAbs in preventing and treating SARS-CoV-2 infection.

5 Jan 2022

FAU researchers urge to prescribe aspirin based on benefit-to-risk not age

Recent guidelines have restricted aspirin use in the primary prevention of cardiovascular disease to patients under 70, and more recent guidance to patients under 60. Yet, the risks of heart attacks and strokes increase markedly with age.

5 Jan 2022

Study leads to reduction in the number of medicines prescribed for older people

A study by researchers at RCSI University of Medicine and Health Sciences of GP-delivered medication for older people led to an overall reduction in the number of medicines prescribed.

5 Jan 2022

Study highlights opioid use disorder treatment access disparities based on Medicaid prevalence

Researchers report that in communities where Medicaid is a more common source of insurance, providers of buprenorphine, an effective treatment for opioid use disorder (OUD), are much less likely to discriminate between Medicaid and privately insured prospective patients, but patients with either type of coverage still face many barriers to obtaining an initial appointment for treatment.

5 Jan 2022

Medical marijuana users brace for shortages as Montana’s recreational market opens

More than a year after voters approved legalizing marijuana for recreational use in Montana, anyone older than 21 can now enter a dispensary and buy cannabis. That has medical marijuana user Joylynn Mane Wright worried.

5 Jan 2022

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

A new study, published on the medRxiv* preprint server, investigated the changes in SARS-CoV-2 antibody levels among HCWs after SARS-CoV-2 vaccination. The study also assessed whether low responders produced sufficient SARS-CoV-2 anti-spike and neutralizing antibodies.

4 Jan 2022

Research demonstrates the safety, feasibility of psilocybin administered at doses of 10mg or 25mg

New research from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King's College London, in partnership with COMPASS Pathways, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously.

4 Jan 2022

SARS-CoV-2 mRNA vaccine boosters crucial in maintaining neutralizing antibodies in HCPs

Researchers evaluate the effects of a third dose of the BNT162b2 mRNA vaccine on antibody titers and breakthrough infections in healthcare workers.

4 Jan 2022

Israeli study confirms drop in BNT162b2 efficacy after six months

Researchers determine whether BNT162b2 vaccination has become less efficient in preventing infection over time.

4 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

Minimal nAb titers against Omicron in the elderly after 3rd dose

Researchers measured titers of cross-protective neutralizing antibodies against SARS-CoV-2 after they had received a third booster dose.

3 Jan 2022

A reliable assessment of COVID-19 vaccine protection duration

Researchers from the University of North Carolina, University of Washington, and the US Food and Drug Administration propose fitting a Cox model with two time indexes, the event times measured from the start of the study in calendar time and the log hazard for the vaccine effect.

30 Dec 2021

The use of monoclonal antibodies against infectious pathogens

Joshua Tan of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health wrote a review article in the journal DNA and Cell Biology about the role of monoclonal antibodies and briefly described a study on bispecific antibodies that neutralize SARS-CoV-2.

30 Dec 2021

An integrated computational methodology for COVID drug prioritization

Previous
1
...
92
93
94
95
96
97
98
...
1434
Next

Pharmaceutical News

Study examines if antidepressants can benefit patients with osteoarthritis

New engineered nanomaterials help capture chemotherapy drugs to avoid tissue damage

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Monoclonal antibody treatment of COVID-19 reduces viral shedding

FAU researchers urge to prescribe aspirin based on benefit-to-risk not age

Study leads to reduction in the number of medicines prescribed for older people

Study highlights opioid use disorder treatment access disparities based on Medicaid prevalence

Medical marijuana users brace for shortages as Montana’s recreational market opens

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

Research demonstrates the safety, feasibility of psilocybin administered at doses of 10mg or 25mg

SARS-CoV-2 mRNA vaccine boosters crucial in maintaining neutralizing antibodies in HCPs

Israeli study confirms drop in BNT162b2 efficacy after six months

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Minimal nAb titers against Omicron in the elderly after 3rd dose

A reliable assessment of COVID-19 vaccine protection duration

The use of monoclonal antibodies against infectious pathogens

An integrated computational methodology for COVID drug prioritization

MRNA boosters shown to increase protection against SARS-CoV-2 Omicron

BNT162b2 booster restores protection following waning of the 2-dose vaccine

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News